PAI-1 (plasminogen activator inhibitor-1) inhibitory activity were synthesized and evaluated for their antithrombotic activity in a rat arterial thrombosis model. Among the synthesized compounds, 5f (T-1776Na) was found to have good selectivity for PAI-1 over other enzymes and high antithrombotic activity.
Plasminogen activator inhibitor-1 (PAI-1) is an effective fast-acting inhibitor of both tissue-type plasminogen activator (t-PA) and two-chain urokinase-type plasminogen activator (tcu-PA), and thus plays an important role in regulation of the fibrinolytic system. 1) Elevated levels of PAI-1 in plasma have been observed in patients with deep vein thrombosis [2] [3] [4] and unstable angina. 5) Furthermore, a number of animal studies have shown that PAI-1 is responsible for fibrinolytic activity in thrombotic and prethrombotic states. [6] [7] [8] Thus, inhibition of PAI-1 activity or reduction of its production may shift the balance between thrombogenesis and thrombolysis towards thrombolysis. In fact, it has been reported that an antibody against PAI-1 can enhance clot lysis and decrease thrombus growth in animal models of venous thrombosis 9) and arterial thrombosis. 10) Therefore, therapeutic inhibition of PAI-1 activity or reduction of its production may be useful for prevention and/or treatment of thrombotic disorders. Indeed, a number of small molecules that inhibit PAI-1 or reduce its production have recently been reported. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] High-throughput screening of Mitsubishi Tanabe chemical libraries led to the discovery of 4-methyl-3-phenyl-5-[1-pyridin-4-ylmeth-(E)-ylidene]-5H-furan-2-one hydrochloride (1a) as a weak PAI-1 inhibitor (IC 50 ϭ24 mM, Fig. 1 ). To improve the inhibitory activity of 1a towards PAI-1, we carried out a series of chemical modifications. In this paper, we describe the synthesis, structure-activity relationships (SAR), and antithrombotic activity of a series of furan-2-one and pyrrolin-2-one derivatives.
Chemistry
The synthetic route of furan-2-one derivatives is shown in Chart 1. The furan-2-one derivatives 1a and 1b were synthesized from 4-methyl-3-phenyl-2,5-dihydrofuran-2-one 7. 21) Treatment of 7 with lithium diisopropylamide (LDA) followed by 4-pyridinecarboxaldehyde and dehydration after methanesulfonylation of the hydroxyl group afforded the products 8a (as a minor product) and 8b (as a major product) in which the 5-pyridylmethylidene parts were introduced. Compounds 8a and 8b were separated by silica gel chromatography and transformed to their HCl salts 1a and 1b, respectively.
4-Methyllactam (pyrrolin-2-one) compounds were synthe- June 18, 2009 sized as shown in Chart 2. The acidic NH proton of 9 22) was first protected with tert-butoxycarbonyl (Boc), and then the 5-pyridylmethylidene parts were introduced under basic conditions. These reactions proceeded with good Z-selectivity in cases of pyrrolin-2-one as well as furan-2-one, and separation of E and Z-products by silica gel chromatography followed by conversion to their HCl salts gave the 5-pyridylmethylidenepyrrolin-2-one compounds 2a-d. Compounds 11b and 11d were then methylated by NaH and MeI, and converted to their HCl salts 3a and 3b, respectively.
Synthesis and Evaluation of Pyrrolin-2-one Compounds, a Series of Plasminogen Activator Inhibitor-1 Inhibitors
The synthetic route of 4-methoxylactam (pyrrolin-2-one) compounds is shown in Chart 3. Compounds 4a and 4b were synthesized from the amide compound 12. After 12 was protected with Boc, the product 13 was cyclized under basic conditions and transformed into the intermediate 15. Compound 4a was obtained from 15 by the same method as 2d in two steps. In the case of compound 4b, methoxymethyl (MOM)-protected 3-hydroxyphenyl was first introduced and the product 17 was converted to the 3-carboxymethoxyphenyl compound 4b by a conventional method.
The 4-phenyllactam or 4-heteroaryllactam (pyrrolin-2-one) compounds 5a-j and 6 were synthesized as follows (Chart 4, 5). 3,4-Diphenyl-1,5-dihydropyrrol-2-one 6 was synthesized in a similar manner as the literature. 23 ) N-(2-Oxo-2-phenylethyl)-2-phenylacetamide 20 was cyclized to give 21 by treatment with acetic anhydride, and cleavage of the N-acetyl group of 21 provided 3,4-diphenyl-1,5-dihydropyrrol-2-one 6. After various substituents were introduced into the 5-position of the N-acetyl compound 21 or N-Boc protected compound 22, several conventional conversions afforded the 4-phenyllactam compounds 5a-h.
In the case of 2-furyl at the 4-position of pyrrolin-2-one, 5i was obtained by introducing a substituent at the 5-position of 27 24) without NH-Boc protection. The thienyl compound 5j was provided in a similar manner as 5i from the commercially available 28 in three steps.
Biological Results and Discussion
The inhibitory activity of furan-2-one and pyrrolin-2-one derivatives for human PAI-1 is summarized in Tables 1 and 2 . The Z-isomer 1b showed better PAI-1 inhibitory activity than the E-isomer 1a. However, these furan-2-one compounds (1a, b) were biologically unstable. This instability was believed to be due to their a,b-unsaturated lactone ring. As such, 1a and 1b were considered inappropriate for inhibition of thrombus formation in vivo. Thus, we tried to transform the lactone ring into a more stable scaffold. The pyrrolin-2-one compounds 2a-d, having a 3 or 4-pyridine ring at the 5-position, were first evaluated. The 3-pyridine compound 2b showed strong inhibitory activity for human PAI-1 (IC 50 ϭ9.8 mM). However, in case of the pyrrolin-2-ones, the inhibitory activity of the E-isomer 2a and that of the 4-pyridine compounds 2c and 2d was low. Furthermore, the Nmethylated compounds 3a and 3b had no PAI-1 inhibitory activity. This led us to examine the SAR of pyrrolin-2-one derivatives with no subsitituent at the 1-position.
Our search for more attractive templates focused on substituents at the 4-position of the pyrrolin-2-one ring (Table  2) . In case of a methoxy group, compounds 4a and 4b exhibited no inhibitory activity. Next, a phenyl group was introduced. The phenylmethylidene compound 5a and the 4-pyridylmethylidene compounds 5b and 6, having no substituent at the 5-position, did not inhibit human PAI-1. However, 3-pyridylmethylidene 5c showed potent inhibitory activity for human PAI-1 (IC 50 ϭ12.6 mM). These findings suggest that hydrophilic groups at the meta-position of the aromatic ring, which extends from the 5-position, are favorable for PAI-1 inhibitory activity. Other hydrophilic substituents, such as alcohol (5d), dimethylacetal (5e) and carboxylic acid (5f), were also examined. Compound 5d did not inhibit human PAI-1, while compound 5e showed a moderate inhibitory activity (IC 50 ϭ7.9 mM). Particularly, compound 5f, having a carboxylic acid group, was found to have potent PAI-1 inhibitory activity (IC 50 ϭ9.6 mM).
Next we focused our efforts on optimizing compound 5f, having a phenoxy acetic acid group. However, compounds 5g and 5h, having a 4-or 2-phenoxy acetic acid moiety, and compounds 5i and 5j, having a furan or thiophene at the 4-position of pyrrolin-2-one ring, exhibited less potent inhibitory activity for human PAI-1 than compound 5f.
In order to select the best compound, the synthesized pyrrolin-2-one compounds were evaluated for their antithrombotic activity in rat arterial thrombosis model. Compounds 2b, 5c, and 5e could not be intravenously infused to rats due to their poor solubility. They were thus considered not to have the desired features for antithrombotic drug. On the other hand, compound 5f, possessing a carboxylic acid group at the 5-position of the pyrrolin-2-one ring, had good solubility and was found to decrease thrombus weight at a dose of 0.5 mg/kg/min. Finally, we evaluated the selectivity of compound 5f for rat PAI-1. Compound 5f inhibited rat PAI-1 with an IC 50 value of 10.3 mM, which is almost equal to its inhibition of human PAI-1. Compound 5f showed no inhibitory effect against the serine proteases thrombin, plasmin, and trypsin, and the serpins antithrombin III, antiplasmin, and antitrypsin at 30 mM. It shows the antithrombotic activity of 5f is thought to be based on its PAI-1 inhibition.
Conclusion
In this study, we examined the structure-activity relationships of a series furan-2-one derivatives. Initial modification led to identification of the pyrrolin-2-one template as a promising scaffold. Optimization of the pyrrolin-2-one derivatives resulted in identification of 5f (T-1776Na) as a potent PAI-1 inhibitor. Compound 5f was selected for further biological evaluation and was found to possess good antithrombotic activity in rat model. Compound 5f was also found to have good selectivity for PAI-1 over serine proteases and serpins. These findings indicate that pyrrolin-2-one derivatives are potential candidates for antithrombotic drugs. Accordingly, compound 5f has been selected as lead compound and further research on its antithrombotic effects are on going.
Experimental
Melting points were measured using a Büchi 535 capillary melting point apparatus and are uncorrected. IR spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer.
1 H-NMR spectra were recorded on a Bruker AC-200 spectrometer (200 MHz) or on a Bruker AVANCE 400 spectrometer (400 MHz) with Me 4 Si as internal standard. Mass spectra were obtained on a ThermoFisher FINNIGAN LXQ or Q-TOF Ultima API mass spectrometer. Elemental analyses were obtained on a PerkinElmer 2400 II (C, H, N) and Dionex DX-320 (S).
4-Methyl-3-phenyl-5-[1-pyridin-4-ylmeth-(E)-ylidene]-5H-furan-2-one Hydrochloride (1a); 4-Methyl-3-phenyl-5-[1-pyridin-4-ylmeth-(Z)
ylidene]-5H-furan-2-one Hydrochloride (1b) 1.6 M n-BuLi in hexane (5.4 ml, 8.6 mmol) was slowly added to a solution of diisopropylamine (1.2 ml, 8.6 mmol) in tetrahydrofuran (THF) (15 ml) at Ϫ78°C. The solution was stirred for 30 min at the same temperature and 4-methyl-3-phenyl-2,5-dihydrofuran-2-one 7 21) (1.0 g, 5.7 mmol) in THF (15 ml) was added dropwise to the solution. The mixture was stirred for 30 min at Ϫ78°C and 4-pyridinecarboxaldehyde (0.92 g, 8.6 mmol) in THF (5 ml) was added dropwise to the mixture. After the addition, the mixture was further stirred for 1 h at Ϫ78°C. Water and ethyl acetate were added to the mixture and the organic layer was separated. The organic layer was then dried and concentrated in vacuo. The resulting residue was dissolved in CH 2 Cl 2 (20 ml), and triethylamine (1. To a 8a (200 mg, 0.76 mmol) solution in CHCl 3 (10 ml) was added 4 N HCl in ethyl acetate (0.19 ml) and the mixture was stirred for 10 min. The reaction mixture was then concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to afford 1a (212 mg, 93%) as a solid. mp Ͼ230°C. Lithium bis(trimethylsilyl)amide in THF (3.5 ml, 3.5 mmol) was slowly added to a solution of 10 (800 mg, 2.93 mmol) in THF (12 ml) at Ϫ78°C. The mixture was stirred for 30 min at the same temperature and 4-pyridinecarboxaldehyde (380 mg, 3.5 mmol) in THF (5 ml) was added dropwise. After the addition, the mixture was further stirred for 30 min at Ϫ78°C and for 16 h at room temperature. Water and ethyl acetate were added to the mixture and the organic layer was separated. The organic layer was dried and concentrated in vacuo. The resulting residue was chromatographed on silica gel to give 80 mg (10%) of 4-methyl-3-phenyl-5-[1-pyridin-3-ylmeth-(E)-ylidene]-1,5-dihydropyrrol-2-one (11a) and 570 mg (74%) of 4-methyl-3-phenyl-5-[1-pyridin-3-ylmeth-(Z)-ylidene]-1,5-dihydropyrrol-2-one hydrochloride (11b) as a solid. mp 180-182°C (11a), 230-231°C (11b).
To a solution of 11b (150 mg, 0.57 mmol) in CHCl 3 (10 ml) was added 4 N HCl in ethyl acetate (0.16 ml) and the mixture was stirred for 10 min. The reaction mixture was concentrated in vacuo, and the resulting residue was triturated with diethyl ether and filtrated to afford 2b (162 mg, 95%) as a solid. mp 311-314°C (dec. 
4-Methyl-3-phenyl-5-[1-pyridin-4-ylmeth-(E)-ylidene]-1,5-dihydropyrrol-2-one Hydrochloride (2c); 4-Methyl-3-phenyl-5-[1-pyridin-4-ylmeth-(Z)-ylidene]-1,5-dihydropyrrol-2-one Hydrochloride (2d) 2c
and 2d, prepared from 10 and 4-pyridinecarboxaldehyde as described in the synthesis of 2a and 2b, were obtained as a solid. 2c yield 6%. mp 331-335°C (dec. To a solution of 11e (90 mg, 0.33 mmol) in CHCl 3 (10 ml) was added 4 N HCl in ethyl acetate (0.09 ml) and the mixture was stirred for 10 min. The reaction mixture was then concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to afford 3a (97 mg, 95%) as a solid. mp 213-215°C. 1 Hydroxy-2-oxo-3-phenyl-2,5-dihydropyrrole-1-carboxylic Acid tertButyl Ester (14) Potassium tert-butoxide (88 mg, 0.78 mmol) was slowly added to a solution of 13 (200 mg, 0.65 mmol) in DMF (10 ml) and the mixture was stirred for 10 min at room temperature. Aqueous saturated ammonium chloride solution, water and ethyl acetate were added to the reaction mixture. The organic layer was separated, washed with water, dried and concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to afford 14 (120 mg, 68%) as a solid. mp 152°C. 
4-

4-Methoxy-3-phenyl-5-[1-pyridin-4-ylmeth-(Z)-ylidene]-1,5-dihydropyrrol-2-one
Hydrochloride (4a) 0.5 M Potassium hexamethyldisilazide in toluene (8.9 ml, 4.45 mmol) was slowly added to a solution of 15 (1.0 g, 2.98 mmol) in THF (20 ml) at Ϫ78°C and the reaction mixture was stirred for 20 min at the same temperature, then at 0°C for 10 min. 4-Pyridinecarboxaldehyde (0.43 ml, 4.47 mmol) was slowly added to the reaction mixture at Ϫ78°C and the mixture was stirred at 0°C for 2 h. After aqueous saturated ammonium chloride solution was added to the reaction mixture, CHCl 3 was added. The organic layer was separated, washed with water and brine, dried and concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated. The crystals obtained were recrystallized from THF to give 120 mg (14%) of 4-methoxy-3-phenyl-5-[1-pyridin-4-ylmeth-(Z)-ylidene]-1,5-dihydropyrrol-2-one (16) as crystals. mp 232-234°C (dec.).
To a solution of 16 (120 mg, 0.43 mmol) in THF (20 ml) was added 4 N HCl in dioxane (0.15 ml) and the mixture was stirred for 10 min. The reaction mixture was then concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to afford 4a (50 mg, 37%) as a solid. mp 227-228°C (dec. 
{3-[3-Methoxy-5-oxo-4-phenyl-1,5-dihydropyrrol-(2Z)-ylidenemethyl]
phenoxy}acetic Acid (4b) 0.5 M Potassium hexamethyldisilazide in toluene (72 ml, 36 mmol) was slowly added to a solution of 15 (7.0 g, 24 mmol) in THF (200 ml) at Ϫ78°C and the reaction mixture was stirred at Ϫ5°C for 30 min. 3-Methoxymethoxybenzaldehyde (3.7 g, 22.3 mmol) was added slowly to the reaction mixture at Ϫ70°C and the mixture was stirred at 0°C for 2 h and at room temperature for 2 h. After aqueous saturated ammonium chloride solution was added to the reaction mixture, ethyl acetate was added. The organic layer was separated, dried and concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated. The crystals obtained were recrystallized from ethyl acetate to give 3.3 g (44%) of 4-methoxy-5-[1-(3-methoxymethoxyphenyl)meth-(Z)-ylidene]-3-phenyl-1,5-dihydropyrrol-2-one (17) 47 (3H, m), 7.52-7.56 (2H, m), 10.09 (1H, s) ϩ . 60% Sodium hydride in oil (300 mg, 7.5 mmol) was slowly added to a solution of 18 (1.8 g, 6.1 mmol) in DMF (50 ml). The mixture was stirred at room temperature for 1 h and bromoacetic acid tert-butyl ester (2.3 g, 11.8 mmol) was added. After the addition, the mixture was further stirred at room temperature for 16 h. Water and ethyl acetate were added to the mixture and the organic layer was separated. The organic layer was washed with water, dried and concentrated in vacuo. The resulting residue was chromatographed on silica gel to give 1.2 g (43%) of {3-[3-methoxy-5-oxo-4-phenyl-1,5-dihydropyrrol-(2Z)-ylidenemethyl]phenoxy}acetic acid tert-butyl ester (19) 3,4-Diphenyl-1,5-dihydropyrrol-2-one (6) Triethylamine (150 ml, 1.08 mol) was slowly added to a suspension of N-(2-oxo-2-phenylethyl)-2-phenylacetamide 20 (32.4 g, 128 mmol) in acetic anhydride (150 ml) at 0°C. After the reaction mixture was stirred at room temperature for 13 h, the mixture was concentrated in vacuo. Water and ethyl acetate were added to the residue, and the organic layer was separated, washed with aqueous saturated citric acid solution, aqueous saturated NaHCO 3 solution and brine, dried and concentrated in vacuo. Toluene (100 ml) was then added to the resulting residue, and the mixture was concentrated in vacuo. The residue was triturated with diethyl ether and filtrated to give 28.2 g (80%) of 1-acetyl-3,4-diphenyl-1,5-dihydropyrrol-2-one (21) ϩ . 28% Sodium methoxide in MeOH (13.6 ml, 65.1 mmol) was slowly added to a suspension of 21 (17.19 g, 62 mmol) in MeOH (400 ml) at 0°C and the reaction mixture was stirred at the same temperature for 1 h. After slow addition of acetic acid (3.71 ml, 65.1 mmol) to the mixture, the mixture was concentrated in vacuo. Water and CH 2 Cl 2 were added to the residue, and the organic layer was separated, washed with brine, dried and concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to give 14.01 g (96%) of 6 as a solid. mp 184-185°C. 2-Oxo-3,4-dipenyl-2,5-dihydropyrrole-1-carboxylic Acid tert-Butylester (22) (Boc) 2 O (12.44 g, 57 mmol) and N,N-dimethyl-4-aminopyridine (348 mg, 2.85 mmol) were added to a suspension of 6 (6.71 g, 28.5 mol) in acetonitrile (300 ml) at 0°C and the mixture was stirred at room temperature for 3 h. Water and ethyl acetate were then added to the mixture, and the organic layer was separated. The organic layer was washed with brine, dried and concentrated in vacuo. The resulting residue was chromatographed on silica gel to give 2.44 g (26%) of 22 as a solid. mp 144-146°C. 3,4-Diphenyl-5-[1-phenylmeth-(Z)-ylidene]-1,5-dihydropyrrol-2-one (5a) 0.5 M Potassium hexamethyldisilazide in toluene (7.2 ml, 3.6 mmol) was slowly added to a solution of 21 (500 mg, 1.8 mmol) and benzaldehyde (0.27 ml, 2.7 mmol) in THF (20 ml) at Ϫ78°C and the reaction mixture was stirred at Ϫ78°C for 30 min and at room temperature for 12 h. After aqueous saturated ammonium chloride solution was added to the reaction mixture, ethyl acetate was added. The organic layer was separated, dried and concentrated in vacuo. The resulting residue was triturated with diisopropyl ether and filtrated. The crystals obtained were recrystallized from ethyl acetate, THF and diisopropyl ether to give 156 mg (27%) of 5a as crystals. mp 243-244°C. {3-[5-Oxo-3,4-diphenyl-1,5-dihydropyrrol-(2Z)-ylidenemethyl]phenoxy}acetic Acid Sodium Salt (5f) Following the synthetic method of 4b, {3-[5-oxo-3,4-diphenyl-1,5-dihydropyrrol-(2Z)-ylidenemethyl]phenoxy}acetic acid (free form) was prepared from 5d as crystals. Yield 61%. mp 247-248°C. To a 397.5 mg (1 mmol) of free form solution in MeOH (10 ml) was added 2 N NaOH aqueous solution (0.5 ml). After the reaction mixture was stirred for 10 min at room temperature, the mixture was concentrated in vacuo. The resulting residue was triturated with diethyl ether and filtrated to give 419 mg (quant.) of 5f as a solid. 95% Sodium methoxide (6.55 g, 115.2 mmol) was added to 29 (14.94 g, 57.6 mmol) in EtOH (50 ml) and the mixture was stirred at reflux for 30 min. After slow addition of acetic acid (6.57 ml, 115.2 mmol) to the mixture at 0°C, the mixture was concentrated in vacuo. Water and CH 2 Cl 2 were then added to the residue, and the organic layer was separated, washed with brine, dried and concentrated in vacuo. The resulting residue was triturated with MeOH and filtrated to give 7.91 g (57%) of 3-phenyl-4-(2-thiophenyl)-1,5-dihydropyrrol-2-one 30 as a solid. mp 224-227°C. A solution of NaOH (260 mg, 6.5 mmol) in water (1 ml) was added to a suspension of 30 (145 mg, 0.6 mmol) and 3-formylphenoxyacetic acid tertbutyl ester (118 mg, 0.5 mmol) in MeOH (2.5 ml). After stirring the mixture at room temperature for 16 h, 2 N HCl aqueous solution (3.25 ml) was added, and the reaction mixture was concentrated in vacuo. Water and CHCl 3 were then added to the residue. The organic layer was separated, washed with aqueous 5% citric acid solution, dried and concentrated in vacuo. The residue was triturated with MeOH and filtrated to give 175 mg (87%) of 5j as a solid. mp 261-263°C. 1 Inhibitory Effect on the Reaction of Human PAI-1 with t-PA The experiment was performed according to the method of Keijer et al. 25) Inhibition of the interaction between t-PA and PAI-1 was determined by measuring residual t-PA activity. Twenty-five microliters of t-PA solution (final conc. 0.2 nM) and 25 ml of assay buffer or PAI-1 solution (PAI-1 was added so as to inhibit t-PA activity by 75% in the absence of test compound) were mixed and incubated with 2.5 ml of a test compound solution (dissolved in DMSO) at 25°C for 15 min. Two hundred microliters of a chromogenic substrate solution (S-2288: H-D-iie-Pro-Arg-pNA) was then added to the mixture, and the whole was incubated at 37°C. The increase in absorbance at 405 nm was continuously (every 5 min) monitored for 2 h with a microplatereader and DA/D min was calculated. The IC 50 value was estimated as the concentration that inhibits PAI-1 activity by 50%.
Antithrombotic Activity of 5f (T-1776Na) in a Rat Model of Arterial Thrombosis Thrombus was induced in the abdominal aorta by electrical stimulation. 26) On the day before the experiment, a catheter-type platinum electrode was implanted into the abdominal aorta through the left femoral artery under Nembutal (Abbot, 50 mg/kg, ip) anesthesia. After the end of the electrode was exteriorized at the back of the neck, a plate-type silver-silver chloride was implanted subcutaneously at the back of the neck at the opposite pole. After suturing the incisions, an electric cell and a variable resistance were placed on the back, each secured by adhesive tape, to act as a power source and fine-tuning the current, respectively. The rats were allowed to recover overnight in individual cages. In the experiment, each electrode was connected to the electric cell and a direct current (200 mA) was applied continuously for 4 h. Test compound or its vehicle was intravenously infused at the dose indicated during electrical stimulation. After current application was stopped, the rats were anesthetized again, and the thrombus formed was removed and its wet weight was measured with an electronic balance. Results are expressed as the meansϮS.E. of 10 rats.
